Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Microdosing a GLP-1 means using less than the FDA-approved treatment range, while regular dosing follows a labeled titration schedule studied in large trials. Microdosing may be discussed for side effects, maintenance, or cost, but it is not FDA-approved and has much less evidence for weight loss than standard dosing [1,2,3].
What does “microdosing” a GLP-1 actually mean?
GLP-1 microdosing usually means using a GLP-1 medication below the FDA-approved therapeutic schedule for that product. FDA labels for semaglutide, tirzepatide, and liraglutide do not define “microdosing,” and they do not list it as an approved regimen for obesity or type 2 diabetes [1,2,3,4,5].
Semaglutide is a GLP-1 receptor agonist sold as Wegovy for chronic weight management and Ozempic for type 2 diabetes uses under their labels; compounded semaglutide may be prepared by a licensed 503A pharmacy for an individual prescription, but compounded drugs are not FDA-approved [1,4,11]. Tirzepatide is a GIP/GLP-1 dual agonist sold as Zepbound for chronic weight management and Mounjaro for type 2 diabetes uses under their labels; compounded tirzepatide is also not FDA-approved [2,5,11].
How microdosing differs from FDA-approved titration schedules
FDA-approved titration schedules start with a labeled initiation dose and increase step by step to studied maintenance doses. For example, the Wegovy label states that semaglutide begins at 0.25 mg once weekly for 4 weeks and is titrated over time to 2.4 mg once weekly for chronic weight management [1].
Microdosing is different because it stays below, pauses before, or otherwise departs from the labeled schedule. That may reduce nausea for some people, but it can also mean less predictable appetite, weight, and glucose effects, and it does not remove label warnings such as gallbladder disease, pancreatitis, hypoglycemia risk with some diabetes drugs, and thyroid C-cell tumor warnings [1,2,9].
Why microdosing has become popular online
People often search for microdosing because standard GLP-1 schedules can cause nausea and other digestive side effects, and brand-name medications can be costly or hard to access. These are real concerns, but online dosing plans cannot review kidney function, pregnancy plans, diabetes medicines, gallbladder history, pancreatitis risk, or contraindications listed in FDA labels [1,2,9].
What are the standard FDA-approved GLP-1 doses?
Standard GLP-1 dosing means following the FDA label for the exact product and reason it is used. The same active ingredient can have different approved uses, target doses, side effects, and warnings depending on whether the label is for obesity, type 2 diabetes, cardiovascular risk reduction, or another listed use [1,2,4,5].
Semaglutide (Ozempic, Wegovy) dosing
Wegovy is semaglutide, a GLP-1 receptor agonist approved by the FDA for chronic weight management in certain adults and adolescents and for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight under its label. The Wegovy label states that the FDA-approved starting dose is 0.25 mg once weekly for 4 weeks, with titration over time to 2.4 mg once weekly [1].
Ozempic is semaglutide approved by the FDA for adults with type 2 diabetes and certain cardiovascular and kidney risk uses under its label; it is not FDA-approved as an obesity medication. The Ozempic label states that semaglutide starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly, with possible labeled increases to 1 mg or 2 mg once weekly when clinically indicated [4].
Semaglutide labels list nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder problems, and acute pancreatitis warnings. They also include a boxed warning about thyroid C-cell tumors and contraindications for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1,4].
Tirzepatide (Mounjaro, Zepbound) dosing
Zepbound is tirzepatide, a GIP/GLP-1 dual agonist approved by the FDA for chronic weight management in certain adults and for obstructive sleep apnea in adults with obesity under its label. The Zepbound label states that tirzepatide starts at 2.5 mg once weekly for 4 weeks, then increases to 5 mg once weekly, with labeled maintenance doses of 5 mg, 10 mg, or 15 mg once weekly [2].
Mounjaro is tirzepatide approved by the FDA for adults with type 2 diabetes. The Mounjaro label states that tirzepatide starts at 2.5 mg once weekly for 4 weeks, then increases to 5 mg once weekly, with possible labeled increases by 2.5 mg after at least 4 weeks on the current dose, up to 15 mg once weekly [5].
Tirzepatide labels list nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, gallbladder warnings, and pancreatitis warnings. They also include a boxed warning about thyroid C-cell tumors and contraindications for medullary thyroid carcinoma history, multiple endocrine neoplasia syndrome type 2, and serious hypersensitivity to tirzepatide or its ingredients [2,5].
Liraglutide (Saxenda, Victoza) dosing
Saxenda is liraglutide, a GLP-1 receptor agonist approved by the FDA for chronic weight management in certain adults and adolescents. The Saxenda label states that liraglutide starts at 0.6 mg once daily and increases weekly through 1.2 mg, 1.8 mg, and 2.4 mg to a 3 mg once-daily maintenance dose [3].
Victoza is liraglutide approved by the FDA for type 2 diabetes and certain cardiovascular risk reduction uses under its label. Liraglutide labels list nausea, vomiting, diarrhea, constipation, gallbladder problems, pancreatitis warnings, and a boxed warning about thyroid C-cell tumors [3,10].
How do microdoses and regular doses compare?
Microdose and regular-dose GLP-1 plans differ most in FDA status, evidence, predictability, and oversight needs. Standard schedules were studied in large trials and reviewed in FDA labeling, while microdosing is not a labeled regimen and has limited direct evidence [1,2,6,7].
| Feature | Microdosing GLP-1 | Regular FDA-approved dosing |
|---|---|---|
| FDA status | Not an FDA-approved regimen; FDA labels do not define GLP-1 microdosing [1,2,3] | Uses FDA-approved titration and maintenance schedules for the product and indication [1,2,3] |
| Evidence for weight loss | Limited direct trial evidence for obesity; results are less predictable, and side effects and contraindications still apply [6,7,9] | Supported by large trials for semaglutide 2.4 mg, tirzepatide 5 mg to 15 mg, and liraglutide 3 mg; individual results vary and GI side effects were common [6,7,8] |
| Side effects | May be easier to tolerate for some people, but nausea, constipation, diarrhea, vomiting, gallbladder issues, and rare pancreatitis can still occur [1,2,9] | Side effects are well described in labels and trials; GI effects are common during dose escalation [1,2,6,7] |
| Cost and access | Sometimes discussed when cost is a barrier, including with compounded options; compounded drugs are not FDA-approved and have extra sourcing and dosing-error concerns [11] | Brand-name products may have insurance rules, supply issues, or high out-of-pocket costs; labels still guide use and risk review [1,2,11] |
| Best fit | May be considered by a clinician for tolerability, access, or maintenance questions, but it is individualized and not label-based [9] | Most evidence-based path when the goal matches an FDA-labeled use such as chronic weight management or type 2 diabetes care [1,2,3] |
What does the evidence say about weight loss at lower doses?
Standard-dose GLP-1 trials show greater average weight loss than placebo, but those results came from specific studied doses and structured follow-up. Benefits must be weighed with common gastrointestinal side effects, contraindications, pregnancy considerations, medication interactions, and the need for ongoing monitoring [1,2,6,7,8].
Clinical trial results at standard doses
In the STEP 1 trial, adults with overweight or obesity without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention. The semaglutide group lost an average of 14.9% of body weight at 68 weeks versus 2.4% with placebo; nausea, diarrhea, vomiting, and constipation were more common with semaglutide, and individual results varied [6].
In the SURMOUNT-1 trial, adults with obesity or overweight without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly. Mean weight loss at 72 weeks was 15.0%, 19.5%, and 20.9% in the tirzepatide groups versus 3.1% with placebo; gastrointestinal adverse events were common, especially during dose escalation, and individual results varied [7].
In the SCALE Obesity and Prediabetes trial, adults with obesity or overweight received liraglutide 3 mg once daily plus lifestyle counseling. At 56 weeks, the liraglutide group lost an average of 8.0% of body weight versus 2.6% with placebo; nausea and vomiting were more common with liraglutide, and individual results varied [8].
What we know — and do not know — about microdoses
Lower GLP-1 doses can have biological effects, especially for glucose measures in type 2 diabetes labels, but that is not the same as proving a microdose plan for obesity. For chronic weight management, pivotal trials and FDA labels support specific titration schedules and maintenance doses, not indefinite microdosing [1,2,4,5].
The evidence gap is important: there are not enough large, long-term trials testing microdosed semaglutide, tirzepatide, or liraglutide for obesity. Clinicians must balance possible tolerability benefits against possible under-treatment, weight regain, nausea, dehydration, gallbladder disease, pancreatitis warnings, contraindications, and unknown long-term outcomes [6,7,9].
Are side effects really lower with microdosing?
GLP-1 side effects are often related to dose escalation, so a lower-dose approach may be easier for some people to tolerate. Still, lower dose does not mean no risk: nausea, vomiting, diarrhea, constipation, abdominal pain, dehydration, gallbladder disease, and pancreatitis warnings are described in labels and trials [1,2,6,9].
People with diabetes who use insulin or sulfonylureas may have a higher risk of low blood sugar when a GLP-1 medicine is added. GLP-1 medicines can also slow stomach emptying, which may affect oral medicines, so medication review matters before any dose change [1,2,5].
Some people should not use certain GLP-1 medicines. FDA labels warn against use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and they warn about serious hypersensitivity reactions [1,2,3].
Who might consider a lower dose?
Lower-dose GLP-1 use may come up when someone has strong digestive side effects, is discussing maintenance, or faces cost and access barriers. This is a clinical decision, not a do-it-yourself plan, because symptoms like vomiting, severe abdominal pain, dehydration, or persistent constipation can signal problems that need medical review [1,2,9].
People sensitive to GI side effects
Nausea and other gastrointestinal side effects are common reasons people struggle with GLP-1 treatment. A clinician may consider slower escalation, a pause, or another plan, but the choice depends on symptoms, lab results, other medicines, pregnancy plans, diabetes risk, and label contraindications [1,2,9].
Maintenance after reaching goal weight
Some people ask about lower doses for weight maintenance after reaching a goal. In the STEP 1 extension, participants regained much of the weight they had lost after semaglutide withdrawal, which suggests obesity often needs long-term care; the study does not prove microdosing is the best maintenance strategy, and side effects and contraindications still matter [12].
Cost-driven considerations
Cost is a common reason people search for microdosing. Compounded semaglutide via a 503A pharmacy and compounded tirzepatide via a 503A pharmacy may be options when legally appropriate and prescribed for an individual patient, but compounded drugs are not FDA-approved and should come from licensed pharmacies with clear sourcing and quality oversight [11].
What are the risks and limits of microdosing?
Microdosing GLP-1 medicines has one major limit: the evidence base is thin compared with standard dosing. A person may have fewer side effects, but they may also get less appetite effect, less weight loss, less glucose effect, or more uncertainty about long-term outcomes; nausea, gallbladder warnings, pancreatitis warnings, and contraindications still apply [1,2,6,7].
- Under-treatment: A dose outside studied ranges may not match the results seen in major obesity trials, and individual results vary [6,7,8].
- Delayed care: Vomiting, dehydration, severe abdominal pain, low blood sugar, or weight regain may be missed without follow-up [1,2,9].
- Medication interactions: GLP-1s can affect insulin, sulfonylureas, and some oral medicines because of hypoglycemia risk or delayed stomach emptying [1,2,5].
- Compounding risk: Compounded products are not FDA-approved, and FDA has warned about dosing errors and adverse events with compounded semaglutide products [11].
- Contraindications: Some people should not use these medicines because of thyroid C-cell tumor warnings, serious allergy history, pregnancy considerations, or other medical factors listed in labels [1,2,3].
How can you access GLP-1 treatment with clinician oversight?
Clinician oversight is important whether you are discussing a brand-name product or a compounded option. A licensed clinician can confirm whether obesity, overweight with weight-related conditions, or type 2 diabetes criteria fit an FDA-labeled use or another appropriate clinical plan, while also checking side effects, contraindications, and drug interactions [1,2,9].
Access can happen through primary care, endocrinology, obesity medicine, or licensed telehealth providers. Chia is one telehealth option that offers clinician-reviewed care for eligible adults, including compounded GLP-1 medications from licensed 503A pharmacy partners when appropriate; a 503A pharmacy compounds medications for individual prescriptions but does not make FDA-approved products [11].
Before prescribing, a clinician may review weight history, body mass index, blood pressure, A1c or glucose history, kidney function, gallbladder and pancreas history, pregnancy plans, current medications, and prior side effects. Follow-up helps adjust the plan if nausea, dehydration, constipation, low blood sugar, or weight regain occurs [1,2,9].
3-min quiz
Considering GLP-1 treatment?
A licensed clinician can help you compare standard dosing, lower-dose approaches, side effects, and compounded options based on your health history. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
Frequently asked questions
No. FDA labels for semaglutide, tirzepatide, and liraglutide include specific titration and maintenance schedules, but they do not define or approve GLP-1 microdosing as a regimen [1,2,3].
Ozempic is semaglutide approved for type 2 diabetes uses under its label, not chronic weight management. Some people may lose weight on lower semaglutide doses, but the strongest obesity evidence is for studied semaglutide 2.4 mg once weekly in STEP 1, where nausea, diarrhea, vomiting, and constipation were more common and individual results varied; compounded drugs are not FDA-approved [1,4,6,11].
Not necessarily. Lower doses may reduce nausea for some people, but they can still cause side effects and may not provide the expected benefit. Contraindications, drug interactions, gallbladder symptoms, dehydration, and pancreatitis warnings still matter [1,2,9].
There is no single lowest effective dose for every person. FDA labels list starting, titration, and maintenance doses by product and indication; for Wegovy, the label states a 0.25 mg once-weekly starting dose for 4 weeks, with titration toward 2.4 mg once weekly for chronic weight management, and it also lists gastrointestinal side effects and thyroid C-cell tumor warnings [1].
Yes. Tirzepatide is a GIP/GLP-1 dual agonist, while semaglutide is a GLP-1 receptor agonist. Their FDA labels, studied doses, approved uses, side effects, and contraindications differ, so they should not be swapped or adjusted without a clinician [1,2,6,7].
It may help some people tolerate treatment, but evidence is limited and it is not an FDA-approved regimen. Nausea, vomiting, constipation, diarrhea, gallbladder warnings, pancreatitis warnings, and thyroid C-cell tumor contraindications still apply, and compounded drugs are not FDA-approved [1,2,9,11].
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved products, and FDA does not evaluate compounded drugs for safety, effectiveness, or quality before they are dispensed. When legally appropriate, they should be prescribed for an individual patient and prepared by a licensed pharmacy with clinician oversight [11].
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health, but a licensed clinician must decide whether treatment is appropriate, and a prescription is not guaranteed.
3-min quiz
Talk with a clinician about GLP-1 options
If you are weighing microdosing against standard dosing, a medical review can help clarify benefits, risks, costs, and safer next steps. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
References
- 1.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 2.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 3.Novo Nordisk. Saxenda (liraglutide) injection prescribing information. U.S. Food and Drug Administration, 2023.
- 4.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 5.Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 6.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 7.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 8.Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 2015.
- 9.Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2022.
- 10.Novo Nordisk. Victoza (liraglutide) injection prescribing information. U.S. Food and Drug Administration, 2023.
- 11.U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. U.S. Food and Drug Administration, 2024.
- 12.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
